During the past decade, Allegheny-Singer Research Institute conducted 34 clinical trials. In the 10-year time frame, 34 clinical trials started and 21 clinical trials were completed, i.e. on average, 61.8% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 19 clinical trials were completed. i.e. 158.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Allegheny-Singer Research Institute" #1 sponsor was "Abbott Medical Devices" with 10 trials, followed by "Edwards Lifesciences" with 3 trials sponsored, "C. R. Bard" with 2 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 2 trials sponsored and "Angel Medical Systems" with 2 trials sponsored. Other sponsors include 31 different institutions and companies that sponsored additional 41 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Allegheny-Singer Research Institute" #1 collaborator was "Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 2 trials as a collaborator, "University of Alabama at Birmingham" with 2 trials as a collaborator and "Allegheny Health Network Research Institute" with 1 trials as a collaborator. Other collaborators include 30 different institutions and companies that were collaborators in the rest 40 trials.

According to Clinical.Site data, the most researched conditions in "Allegheny-Singer Research Institute" are "Coronary Artery Disease" (4 trials), "Aortic Valve Stenosis" (3 trials), "Stroke" (3 trials), "Heart Failure" (2 trials) and "Multiple Sclerosis, Relapsing-Remitting" (2 trials). Many other conditions were trialed in "Allegheny-Singer Research Institute" in a lesser frequency.

Most popular intervention types in "Allegheny-Singer Research Institute" are "Device" (23 trials), "Drug" (21 trials), "Other" (9 trials), "Procedure" (4 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Guselkumab" (2 trials), "14-Gene Prognostic Assay" (1 trials), "AMPLATZER™ PFO Occluder" (1 trials) and "Abraxane (Induction)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Allegheny-Singer Research Institute" are 53 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Allegheny-Singer Research Institute". 1 are not yet recruiting, 10 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in Allegheny-Singer Research Institute, undefined suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in Allegheny-Singer Research Institute, 0 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 21 trials that are defined as “Not Applicable".